美国食品和药物管理局批准疫苗的速度、证据和安全性特征。
Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration.
机构信息
Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.
出版信息
JAMA Intern Med. 2021 Apr 1;181(4):559-560. doi: 10.1001/jamainternmed.2020.7472.
Abstract
This cross-sectional study evaluates all of the novel vaccines approved by the US Food and Drug Administration over the last decade.
摘要
这项横断面研究评估了过去十年中所有获得美国食品和药物管理局批准的新型疫苗。
相似文献
1
Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration.美国食品和药物管理局批准疫苗的速度、证据和安全性特征。
JAMA Intern Med. 2021 Apr 1;181(4):559-560. doi: 10.1001/jamainternmed.2020.7472.
2
Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010-2020.2010 - 2020年美国食品药品监督管理局疫苗批准所需试验参与者的人口统计学特征
J Gen Intern Med. 2022 Feb;37(3):700-702. doi: 10.1007/s11606-021-06670-3. Epub 2021 Mar 3.
3
Vaccines in the pipeline: the path from development to use in the United States.正在研发的疫苗：从研发到在美国投入使用的历程。
Pediatr Ann. 2013 Aug;42(8):146-52. doi: 10.3928/00904481-20130723-08.
4
Vaccine licensure: a proposal to meet changing needs.
Ann N Y Acad Sci. 1995 May 31;754:368-76. doi: 10.1111/j.1749-6632.1995.tb44472.x.
5
Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada.比较美国食品药品监督管理局、欧洲药品管理局和加拿大卫生部批准的 COVID-19 疫苗。
JAMA Netw Open. 2021 Jun 1;4(6):e2114531. doi: 10.1001/jamanetworkopen.2021.14531.
6
Vaccines on a Shelf: Vaccines in Development Often Sit Around Untested.
Tex Med. 2018 Sep 1;114(9):42-45.
7
Trends in US approvals: new biopharmaceuticals and vaccines.美国审批动态：新型生物制药与疫苗
Trends Biotechnol. 2006 Jul;24(7):293-8. doi: 10.1016/j.tibtech.2006.05.003. Epub 2006 Jun 6.
8
Drugs and vaccines for the common defense: refining FDA regulation to promote the availability of products to counter biological attacks.用于共同防御的药品和疫苗：完善美国食品药品监督管理局的监管以促进应对生物攻击产品的可及性
J Contemp Health Law Policy. 2002 Winter;19(1):37-116.
9
Development and approval of vaccines in the United States.
Isr J Med Sci. 1986 Mar-Apr;22(3-4):268-71.
10
Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration.美国食品药品监督管理局近期批准的仿制药特点。
JAMA Netw Open. 2019 Oct 2;2(10):e1913029. doi: 10.1001/jamanetworkopen.2019.13029.
引用本文的文献
1
De-risking vaccine development: lessons, challenges, and prospects.降低疫苗研发风险：经验教训、挑战与前景。
NPJ Vaccines. 2025 Jul 30;10(1):177. doi: 10.1038/s41541-025-01211-z.
2
Regulatory Review Time of Vaccine Approvals in China Between 2005 and 2024.2005年至2024年中国疫苗批准的监管审查时间
JAMA Netw Open. 2025 Jun 2;8(6):e2518255. doi: 10.1001/jamanetworkopen.2025.18255.
3
Anaphylactic Reactions to COVID-19 Vaccines: An Updated Assessment Based on Pharmacovigilance Data.新型冠状病毒肺炎疫苗的过敏反应：基于药物警戒数据的最新评估
Vaccines (Basel). 2023 Mar 8;11(3):613. doi: 10.3390/vaccines11030613.
4
Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.儿童和青少年接种 mRNA COVID-19 疫苗后的过敏反应发生率：EudraVigilance 报告数据的分析。
Vaccine. 2023 Mar 31;41(14):2382-2386. doi: 10.1016/j.vaccine.2023.02.067. Epub 2023 Feb 27.
5
Neutralizing antibody responses in healthcare personnel after three doses of mRNA BNT162b2 vaccine and association with baseline characteristics and past SARS-CoV-2 infection.医护人员接种三剂 mRNA BNT162b2 疫苗后的中和抗体反应及其与基线特征和既往 SARS-CoV-2 感染的关系。
Vaccine. 2022 Sep 22;40(40):5752-5756. doi: 10.1016/j.vaccine.2022.08.031. Epub 2022 Aug 19.
6
Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.与 COVID-19 疫苗相关的过敏反应发生率与其他疫苗相当。
Vaccine. 2022 Jan 21;40(2):183-186. doi: 10.1016/j.vaccine.2021.11.066. Epub 2021 Nov 27.
7
A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021.对希腊雅典大都市区第三次 COVID-19 大流行浪潮的演变进行研究，通过两项横断面血清流行病学调查：2021 年 3 月和 6 月。
J Med Virol. 2022 Apr;94(4):1465-1472. doi: 10.1002/jmv.27465. Epub 2021 Dec 4.
8
[Vaccine against COVID-19].[新型冠状病毒肺炎疫苗]
Rev Esp Quimioter. 2021 Dec;34(6):559-598. doi: 10.37201/req/085.2021. Epub 2021 Jun 28.
9
Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada.比较美国食品药品监督管理局、欧洲药品管理局和加拿大卫生部批准的 COVID-19 疫苗。
JAMA Netw Open. 2021 Jun 1;4(6):e2114531. doi: 10.1001/jamanetworkopen.2021.14531.
10
Challenges and Issues of Anti-SARS-CoV-2 Vaccines.抗SARS-CoV-2疫苗的挑战与问题
Front Med (Lausanne). 2021 May 14;8:664179. doi: 10.3389/fmed.2021.664179. eCollection 2021.
Zotero 插件